Abstract
Chronic ITP is a common hematologic illness. Approximately three fourths of the patients respond to corticosteroids or splenectomy and need no further treatment. Patients refractory to these two therapeutic approaches are relatively resistant to present forms of treatment and are at much greater risk for morbidity and mortality. Future clinical studies evaluating therapy in this refractory group would be best performed in a cooperative group setting in which large numbers of patients could be treated in a prospective randomized manner.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage
-
Adult
-
Antibodies, Monoclonal / therapeutic use
-
Ascorbic Acid / therapeutic use
-
Autoimmune Diseases / therapy
-
Azathioprine / therapeutic use
-
Colchicine / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Cyclosporins / therapeutic use
-
Danazol / therapeutic use
-
Female
-
Humans
-
Methylprednisolone / administration & dosage
-
Plasmapheresis
-
Platelet Transfusion
-
Pregnancy
-
Pregnancy Complications, Hematologic
-
Purpura, Thrombocytopenic / immunology
-
Purpura, Thrombocytopenic / therapy*
-
Splenectomy
-
Vinca Alkaloids / therapeutic use
-
gamma-Globulins / administration & dosage
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Cyclosporins
-
Vinca Alkaloids
-
gamma-Globulins
-
Cyclophosphamide
-
Azathioprine
-
Danazol
-
Ascorbic Acid
-
Colchicine
-
Methylprednisolone